154361-50-9 | Capecitabine

Chemical type

• Oral fluoropyrimidine prodrug

^[1]

• Fluoropyrimidine pro-drug

^[2]

Key properties

• Converts to 5-FU (5-fluorouracil) via thymidine phosphorylase
• Induces apoptosis through caspase activation
• Down-regulates NF-κB
• Upregulates caspase-3 and caspase-9
• May down-regulate p53 in single treatment

^[1]

• An orally administered chemotherapeutic agent that is metabolized to 5-fluorouracil (5-FU) in the body

^[2]

• Chemotherapeutic agent for colorectal cancer
• Part of regimens like FOLFOX or as monotherapy
• Combination with irinotecan and 17-AAG for enhanced apoptosis
• Treatment of HT-29 colon cancer cells

^[1]

• First-line treatment for metastatic colorectal cancer (mCRC); used in combination therapy with PD-1 inhibitors

^[2]

Classification by use

• Chemicals used in cancer chemotherapy
• Chemicals used as prodrugs
• Chemicals used as apoptosis inducers

^[1]

• Chemotherapy agent

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29), Annals of Medicine and Surgery, Volume 78, June 2022, 103850
2. [Cite:2] Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors, Iscience, Volume 28, Issue 12, 19 December 2025, 114202